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a  b  s  t  r  a  c  t
Hendra  and  Nipah  viruses  (HeV  and  NiV) are  closely  related  zoonotic  pathogens  of the  Paramyxoviridae
family.  Both  viruses  belong  to the Henipavirus  genus  and  cause  fatal  disease  in  animals  and  humans,
though  only  HeV  is endemic  in  Australia.  In  general  and  due  to the  acute nature  of the disease,  agent
detection  by PCR and  virus isolation  are  the  primary  tools  for diagnostic  investigations.  Assays  for  the
detection  of  antibodies  against  HeV  are  fit  more  readily  for the  purpose  of surveillance  testing  in dis-
ease  epidemiology  and  to  meet  certification  requirements  in  the  international  movement  of horses.  The
first generation  indirect  ELISA  has  been  affected  by  non-specific  reactions  which  must  be resolved  using
virus  neutralisation  serology  conducted  at laboratory  bio-safety  level  4  containment  (PC4).  Recent  devel-
opments  have  enabled  improvements  in the  available  serology  assays.  The  production  of  an expressed
recombinant  truncated  HeV  G  protein  has  been  utilised  in  ELISA  and  in  Luminex-based  multiplexed
microsphere  assays.  In  the  latter  format,  two  Luminex  assays  have  been  developed  for  use  in  henipavirus
serology:  a binding  assay  (designed  for antibody  detection  and differentiation)  and  a  blocking  assay
(designed  as  a surrogate  for virus  neutralisation).  Equine  and  canine  field  sera  were  used to evaluate  the
two Luminex  assays  relative  to ELISA  and  virus  neutralisation  serology.  Results  showed  that  Luminex
assays  can  be  effective  as  rapid,  sensitive  and specific  tests  for the  detection  of  HeV  antibody  in  horse  and
dog  sera.  The  tests  do not  require  PC4  containment  and are  appropriate  for  high  throughput  applications
as  might  be required  for disease  investigations  and other  epidemiological  surveillance.  Also,  the results
show  that  the Luminex  assays  detect effectively  HeV  vaccine-induced  antibodies.
© 2014  Elsevier  B.V.  All  rights  reserved.
1. Introduction
Hendra virus (HeV) and Nipah virus (NiV) belong to the Heni-
pavirus genus within the Paramyxoviridae family (Eaton et al., 2007).
HeV was detected first following an outbreak of a severe and fatal
respiratory disease in a large racing stable in the suburb of Hendra,
Brisbane in 1994. Since the initial HeV outbreak, sporadic spill-over
events have occurred annually in Australia across Queensland and
northern New South Wales. The natural reservoir of these zoonotic
agents is within the genus Pteropus (Haplin et al., 2011), commonly
known as fruit bats or flying foxes. This disease is usually fatal in
horses with over 80 horses having died or been euthanised due to
infection with HeV; furthermore four of the seven humans known
Abbreviations: HeV, Hendra virus; NiV, Nipah virus; %P, percent positive; %I,
percent inhibition; MFI, median fluorescence intensity.
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to be infected with HeV have died (Marsh and Wang, 2012). In 2011,
a healthy dog on a HeV affected Qld property was also found to have
high levels of neutralising antibody against HeV (Croser and Marsh,
2013). More recently in November 2012, a commercial equine vac-
cine against HeV (Equivac HeV, Zoetis Australia P/L) was released
for use in Australia (Mendez et al., 2013; Broder et al., 2013). How-
ever, a henipavirus vaccine for humans will take many more years
to develop (Middleton, 2012).
Initially NiV emerged in pigs in Malaysia in 1998 (Chua et al.,
2000); by April 1999, 106 human deaths had occurred in Malaysia
and Singapore (Marsh and Wang, 2012). No further outbreaks of
NiV have been reported in Malaysia, however, in separate outbreaks
the virus continues to spill over and cause disease in other countries
such as Bangladesh and India.
The henipavirus genome is a non-segmented, negative-strand
RNA. The genes encode six major structural proteins; the nucleo-
capsid (N), phosphoprotein (P), matrix protein (M), fusion protein
(F), attachment glycoprotein (G) and the large polymerase
(L) (Wang et al., 2001). The two major membrane-anchored
0166-0934/$ – see front matter © 2014 Elsevier B.V. All rights reserved.
http://dx.doi.org/10.1016/j.jviromet.2014.01.010
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glycoproteins are required for infection of a permissive host cell.
The F glycoprotein mediates pH-independent membrane fusion
between the virus and its host cell (Bossart et al., 2005). The G
glycoprotein is the attachment protein which binds the host cell
via the Ephrin B2 or Ephrin B3 receptors (Bossart et al., 2008).
The G protein of NiV and HeV share 83% nucleotide homology
(Wang et al., 2001) and cross-reactive antibodies against the G pro-
tein have been observed between the two viruses (Bossart et al.,
2005).
Laboratory diagnosis of equine infection following a HeV spill-
over event is critical to management of potentially exposed persons
and animals located on infected premises. Currently, all diagnostic
submissions for HeV exclusion received at CSIRO’s Australian Ani-
mal  Health Laboratory (AAHL) are tested by PCR and virus isolation.
Due to the fulminant and lethal course of the disease, serology is less
frequently definitive in the diagnosis of acute infection. However
the technique is appropriate for “proof of freedom” of animals on
affected properties, surveillance and regulation testing of horses
prior to international transport. At the Australian Animal Health
Laboratory (AAHL), HeV serology presently is conducted by indirect
ELISA using either inactivated virus (Daniels et al., 2001; OIE, 2009)
or the more recently introduced recombinant-expressed protein
(Wang and Daniels, 2012; Colling et al., 2013). The latter employs
a form of the G protein (sG), truncated for enhanced solubility
(Bossart et al., 2005). Currently, all serum reactors (positive and
indeterminate) in the iELISAs are resolved by a virus neutralisation
assay which must be performed under strict bio-containment pro-
cedures in a PC4 laboratory. The interpretation and validation of
the HeV iELISAs are complicated by the lack of a large number of
test results for positive sera and by the frequency of non-specific
reactions, particularly in the whole virus ELISA. These also must be
resolved for specificity by virus neutralisation serology. The devel-
opment of a rapid and safe microsphere immuno-assay (Luminex
assay) which can be performed in a PC2/PC3 laboratory, will aid in
diagnostic surveillance of this disease.
Two Luminex-based fluorescent microsphere assays have been
developed using an approach described previously by Bossart et al.
(2007) for detection of antibody against henipaviruses. The target
antigen for both assays is recombinant-expressed sG, but the assays
are designed separately in total antibody-binding and restricted
receptor-blocking formats. The Luminex binding assay was  used
for antibody detection and differentiation of HeV and NiV whereas
the Luminex blocking assay was designed as a surrogate for virus
neutralisation. The detection of HeV-specific antibodies in sera
from convalescent horses following HeV infection in Australia using
the henipavirus Luminex binding and blocking assays was  first
described by Bossart et al. (2007). In addition, these Luminex assays
have been used for further serological studies to detect henipavirus
antibodies in bats and other species internationally including; West
African fruit bats and domestic pigs (Hayman et al., 2008; Hayman
et al., 2011; Peel et al., 2012, 2013), Pteropid bats in Papua New
Guinea (Breed et al., 2010) and Pteropus vampyrus bats in Indonesia
(Sendow et al., 2013). Recently, the Luminex microsphere assay was
used to assess HeV infection in the mouse model (Dups et al., 2012)
and to confirm HeV infection in human cases by Queensland Health
(Playford et al., 2010).
In 2011, a year with an unusually high occurrence of HeV
infections (18 outbreaks) in Australia (Mahalingam et al., 2012),
three dogs from a HeV infected property undergoing quarantine in
Mount Alford, Queensland were assessed by HeV ELISAs and HeV
virus neutralisation serology at AAHL (Croser and Marsh, 2013).
This was the first report of a dog infected naturally with HeV in
Australia.
In this study, the Luminex assays were characterised further for
use in detection of HeV specific antibodies in sera from infected and
non-infected animals including horses and dogs; results have been
evaluated against assessments using ELISA and virus neutralisation
serology assays.
2. Materials and methods
2.1. Animal sera
All field horse and dog sera tested were derived as diagnos-
tic samples submitted to the AAHL; sera were neat or diluted 1:5
in PBS containing 0.5% Tween 20 and 0.5% Triton-X100, and heat
treated at 56 ◦C for 30 min  prior to use. A range of horse, pig, goat,
rabbit and guinea pig anti-sera for use in analytical specificity (HeV-
uninfected) assessments were variously derived from naturally or
infected experimentally animals. Sera from HeV vaccinated horses
(AAHL job 12-03417) were received for HeV serology assessment,
though without details of vaccination time or doses.
2.2. Henipavirus Luminex binding and blocking assays
The multiplex microsphere assays have been described previ-
ously by Bossart et al. (2007). Briefly, for both assays, HeV or NiV
soluble G (sG) proteins (Bossart et al., 2005) were coupled to indi-
vidual microsphere sets. In both assays a predetermined number
of polystyrene or magnetic beads (Fisher Biotec Pty Ltd, Australia)
were added to each well and then mixed with test sera at a dilution
of 1:100 (binding assay) or 1:50 (blocking assay). In the binding
assay, bound antibody was  detected using biotinylated Protein A
(Pierce, Rockford, USA) together with biotinylated Protein G (Pierce,
Rockford, USA) followed by streptavidin–phycoerythrin (Qiagen
Pty Ltd, Australia). Results were recorded as median florescent
intensity (M.F.I.), or transformed as a percentage relative to the
MFI  for the positive control (%P): [(MFI test serum)/(MFI positive
control serum)] × 100.
For the receptor blocking assay, the presence of HeV antibod-
ies in the serum was  detected by the ability to block biotinylated
Ephrin B2 (Sapphire Bioscience Pty Ltd, Australia) which other-
wise binds directly to soluble G protein-coated beads (Bossart
et al., 2008). Streptavidin–phycoerythrin was added for detection
of bound Ephrin B2. Low MFI  values indicated henipavirus anti-
bodies blocked successfully the binding of the receptor to sG. The
results were recorded as a percentage inhibition and raw MFI read-
ings were converted to percentage inhibition using the following
formula: (1 − [(MFI test serum)/(MFI negative serum)] × 100.
Both assays were read using a Bio-Plex Protein Array System
integrated with Bio-Plex Manager Software (v 4.1) (Bio Rad Labo-
ratories, Inc., CA, USA) for data acquisition and analysis.
2.3. HeV ELISAs
2.3.1. HeV antibody indirect ELISA (HeV iELISA)
This ELISA, using detergent disrupted/inactivated virus antigen
derived from whole cell lysates of HeV-infected Vero cells has been
previously described by Daniels et al. (2001). In brief, NUNC Max-
isorb plates were coated with HeV infected and non-infected (mock
antigen) cell lysates diluted in carbonate buffer (pH 9.6) for 1 h at
37 ◦C. Coating and subsequent binding steps were followed by a
four cycle rinse with wash buffer (PBS + 0.05% Tween 20). Sera were
assessed at a 1:100 dilution in wash buffer with added 1% skim milk
powder for an incubation period of 1 h at 37 ◦C. Bound antibody was
reacted with a Protein A/G-HRP conjugate (Pierce, Rockford, USA),
30 min  at 37 ◦C. TMB  substrate (Sigma-Aldrich Pty Ltd, Australia)
was reacted for 7–10 min  before addition of 1 M H2SO4. Plates were
read for absorbance at optical density 450 nm.  After background
subtraction, a threshold optical density 0.2 was assigned to differ-
entiate positive reactor from negative sera. All reactive sera were
retested in virus neutralisation serology. Significant reactions on
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Fig. 1. Limit dilution titration of Luminex binding () and blocking assays () for HeV
sG  using a positive serum (Tho) with a virus neutralisation titre 1024.
the mock antigen in association with above threshold OD detec-
tions were qualified for interpretation as “non-specific reactors”.
2.3.2. HeV antibody indirect ELISA (HeV sG-iELISA)
The ELISA used HeV sG antigen coated at a concentration of
0.23 g/ml. After a coating incubation (1 h at 37 ◦C), the plate was
blocked with skim milk for 30 min  and washed with PBST. Test
sera were diluted 1:100, added to the plate and shaken for 1 h
at 37 ◦C. Bound antibody was detected by using anti equine-HRP
(Sigma-Aldrich Pty Ltd, Australia) or Protein A/G-HRP conjugate
(Pierce, Rockford, USA) and a TMB  substrate. Plates were read for
absorbance at optical density 450 nm.  After subtraction of back-
ground (taken as the OD from the negative control serum), ODs
were transformed to a ratio relative to a low positive control serum
(average OD approximately 0.5) and a signal to positive S/P ratio
was calculated. A threshold S/P of 0.4 was assigned to differentiate
positive reactor from negative sera. This assay is specific for equine
sera due to the anti-equine conjugate used in the test. As for the
HeV iELISA, all positive reactor sera in the sG-iELISA were retested
in virus neutralisation serology.
2.4. HeV virus neutralisation serology
A standard virus neutralisation in microplate format was  used
for assessing sera for neutralising antibody against HeV (Bossart
et al., 2007; OIE, 2009). The test used Vero cells and a virus con-
centration of 100 TCID50/well. Sera were assessed from an initial
dilution of 1:2 and were incubated with virus in a 96 well plate
for 30 min  at 37 ◦C. Vero cells were added and the plates incubated
for 4 days at 37 ◦C in a CO2 incubator. Cell monolayers were scored
for the presence of cytopathic effect (CPE) and serum neutralisa-
tion titres were determined as the reciprocal of the serum dilution
where no CPE was evident.
3. Results
3.1. Analytical sensitivity for the Luminex assays
To determine the analytical sensitivity for the henipavirus
Luminex binding assay, a titration of a seropositive field infection
serum (Tho), with a virus neutralisation titre of 1:1024 was per-
formed (Fig. 1). The lower asymptote end point for the curve was
approached at an MFI  value of approximately 865 reaching this
point at a dilution of 1:3200. Analytical sensitivity was derived
from a third order polynomial regression curve fitted to the four
Fig. 2. Detection of henipavirus antibodies in a panel of sera from a range of Paramy-
oxviruses,  Flaviviruses and Alphaviruses using the Luminex binding and blocking
assays.
lowest data points (r2 = 1) and applying assay threshold MFI  value of
1500. Using HeV Luminex binding assay, the end-point dilution for
positive signal detection was  1:2125. This represents an analytical
detection range of approximately 2 times the assigned virus neu-
tralisation titre (1024). The positive serum (Tho) was designated as
a positive control for use in subsequent assays. In the binding assay
and for the purpose of a normalising data, MFI  values for test sera
were transformed relative to the MFI  value for the positive serum
to yield a percentage positive (%P) value. The threshold was  set at
5%P, being approximately 1500 MFI.
The serum was tested similarly in the Luminex blocking assay,
reaching the lower asymptote at a dilution of 1:800. Using a pos-
itive/negative threshold of 15 percent inhibition (%I), detection
to threshold spanned a 1:475 dilution range which is less than
the virus neutralisation range by approximately half. Relative to
the binding assay, the detection range for the blocking assay was
reduced by a factor of 4.48. Taking into account the initial dilution
(1:100 for binding assay and 1:50 for blocking assay), the binding
assay had an analytical sensitivity approximately 9 times that of
the blocking assay.
3.2. Analytical specificity of Luminex assays
In order to assess the analytical specificity of the henipavirus
Luminex binding and blocking assays anti-sera against a range of
Paramyxoviridae, Flaviviruses and Alphaviruses were tested.
In the binding format of the assay, one serum not raised against
Henipavirus was marginally above the 5% provisional threshold
with a reaction level of 7%P (Fig. 2). This reactive serum was  an
experimentally produced equine antiserum against eastern equine
encephalitis virus. In the blocking format all non-Henipavirus
antisera were not reactive relative to the set threshold of 15%I. Anti-
serum against NiV cross reacts to a high level in both binding and
blocking assays.
The HeV iELISA and sG-ELISA were also assessed using this panel
of sera. Frequently interpretation of results for the HeV iELISA
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(using the whole virus antigen preparation) was influenced by sig-
nificant non-specific reactions evident as high OD values (greater
than 0.2) against the mock antigen. The HeV sG-iELISA showed a
high level of analytical specificity for HeV antibodies as all non-
Henipavirus sera were negative.
3.3. Diagnostic specificity of Luminex assays
Two panels of HeV antibody negative sera as determined by
virus neutralisation and/or ELISA serology were tested in Luminex
binding and blocking assays to provide evidence for diagnostic
specificity.
One hundred and thirty five horse field sera which previously
had tested negative in the HeV sG-iELISA were examined in the
Luminex binding and blocking assays. The results in the binding
assay (Table 1) showed that sera had a mean %P value of 0.4 with
standard deviation of 0.12. In the receptor blocking assay, test sera
displayed 0.8 ± 1.42 (mean ± standard deviation) percent inhibi-
tion; the positive control sera gave results in the range 93 to 95%I.
During the course of this study, the use of polystyrene beads was
changed to magnetic beads. The results observed here showed good
correlation between using magnetic or polystyrene beads (Table 1).
An additional panel (n = 145) of HeV virus neutralisation neg-
ative sera, grouped by an indeterminate result following testing
in the HeV iELISA were further assessed by HeV Luminex assays.
The binding assay showed test sera to have an average 1.2 ± 0.82
(mean ± standard deviation) %P with all results below the provi-
sional 5%P threshold, however one serum reacted to 4.1%P. This
serum panel were also examined by the Luminex blocking assay,
giving an average %I of 2.42 with a standard deviation of 2.98 and a
maximum of 12.4. The results for these sera which were problem-
atic when tested by ELISA differ from results testing other negative
sera; suggesting that the blocking format may  be more affected by
serum sample characteristics than the binding assay.
In addition, sera with an assigned negative status (designated
by clinical and or serological data for virus neutralisation and/or
ELISA), total testings were made, respectively, of 277 (binding
assay) and 267 (blocking assay) sera (Fig. 3). Results provided sup-
port for the assigned provisional cut-off thresholds; 5%P control for
the binding assay and 15%I for the receptor blocking assay.
3.4. Use of Luminex assays for post infection and post vaccination
sera
The Luminex assays were assessed further using sera derived
from horses naturally infected with HeV during the original out-
break in 1994, and from other HeV outbreaks. A total of twenty
one post infection sera were examined by ELISA, virus neutralisa-
tion and the Luminex assays. All sera tested were positive by virus
neutralisation and above the cut off value of 1000 MFI using the
Luminex binding assay. The results showed the higher the virus
neutralisation titre, the higher the Luminex binding and blocking
results using both HeV sG and NiV sG coated beads (Table 2).
Fifty four sera from horses that had been vaccinated with the
commercially available Hendra virus vaccine (Equivac HeV) which
contains the soluble G protein were assessed by the ELISA, virus
neutralisation and Luminex binding and blocking assays. The HeV
iELISA produced inclusive results due to binding in the mock anti-
gen wells, whereas the sG-iELISA returned positive results for all the
sera. Using the Luminex assays, the vaccinated horse sera displayed
high levels of greater than 50.3%P control in the binding assay and
above 22%I for the blocking assay using the beads coated with sol-
uble G (Fig. 4). Serum from one horse (12-03417-0001) produced
low results in the Luminex and ELISA however this correlated with
the virus neutralisation negative result for this serum.
Fig. 3. Distribution of Luminex binding and blocking assay results for sera previously
determined to be henipavirus antibody negative (binding assay n = 277, blocking
assay n = 267), 21 post-infection sera and 54 post vaccination sera. Status assigned by
clinical and or serological data (virus neutralisation and/or ELISA). Luminex binding
and blocking assay thresholds were set at 5%P and 15%I, respectively.
Fig. 4. Correlation of HeV virus neutralisation antibody with HeV  sG iELISA, Luminex
binding and Luminex blocking assay for sera collected from fifty four horses follow-
ing vaccination with Equivac HeV. Note sera with titres of greater than 256 were
assigned a nominal titre of 512 for the purpose of representation in the plot.
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Table  1
Results using magnetic or polystyrene beads in Luminex binding and blocking assays of horse field sera determined as negative by HeV sG iELISA.
Luminex binding assay (MFI) Luminex blocking assay (% inhibition)
Magnetic HeV sG Polystyrene HeV sG Magnetic HeV sG Polystyrene HeV sG
No serum control 43 43 0 0
Neg  horse serum 118 92 −1 −1
Pos  serum (Tho) 24,989 23,599 93 96
Pos  serum (Tam) 26,666 25,882 95 97
Test  sera (average ± standard deviation)1 99 ± 301 66 ± 291 0.8 ± 1.422 0.52 ± 1.272
1 135 normal horse sera were assessed in the Luminex binding assay.
2 126 normal horse sera were assessed in the Luminex blocking assay.
3.5. Review of assay thresholds
Receiver-operator curve (ROC) analysis using assigned posi-
tive or negative status of all sera assessed by Luminex binding
and blocking assays was used to evaluate provisional thresholds.
Results are summarised in Table 3 suggest that an improvement
in assay performance could be obtained by marginal alterations to
the provisional thresholds, specifically, the binding assay from 15 to
12.45 and the blocking assay from 5 to 3.67. However confidence
intervals have considerable overlap and the different thresholds
affected the result determination for only one serum. As a work-
ing resolution, a zone of equivocal determination for results falling
between 10 and 15 for the binding assay and from 3 to 5 in the
blocking assay was defined. Samples with results falling within
these zones would be subject to qualified reporting and/or addi-
tional assessment.
3.6. Use of Luminex assays for naturally infected dog sera
The two serum samples taken on the 20th and 26th July 2011
(2011/Mount Alford, QLD no. 1 and 2011/Mount Alford, QLD no. 2)
from a naturally HeV-infected dog were examined together with
dog sera from other HeV infected premises obtained throughout
2011. The Luminex binding assay showed that a high level of HeV
specific antibodies were present in the two blood samples taken
from the HeV infected dog with results of 22,182 MFI  and 12,241
MFI  (Table 4). All other dog sera tested in the Luminex binding
assay had MFI  values below 230. In the Luminex blocking assay the
two blood samples taken from the HeV infected dog had 88% and
61% inhibition while results for all the other dog samples tested
showed very low levels of inhibition below 3%. All the dog samples
were also examined by HeV iELISA, sG-iELISA and virus neutral-
isation. Many of the dog sera tested in the HeV iELISA produced
non-specific reactors preventing conclusive determination by that
assay. The HeV sG-iELISA also produced some non-specific positive
results as determined by the correlating Luminex and HeV virus
neutralisation assays showing a negative antibody status. In com-
parison to the ELISAs, the Luminex assays look to be a useful tool
for testing naturally HeV infected dog sera.
4. Discussion
Serology for BSL 4 agents can be problematic in the absence
of appropriate containment facilities; hence the development of
assays that do not require live virus is advantageous. Assays
applied at the time of initial emergence of the disease will gener-
ally require technical and interpretive refinement as observations
and data accumulate. However, the validation of these assays for
new or emerging viruses frequently presents additional challenges
due to the lack of well characterised sera. This is exacerbated in
such fulminant disease as HeV by the high early mortality and a
policy of immediate euthanasia upon confirmed detection. Sero-
logy procedures applied to date at the Australian Animal Health
Laboratory (PC3 and PC4 containment) have included virus neu-
tralisation, ELISA and more recently the Luminex-based fluorescent
bead assays. The availability of recombinant expressed proteins has
Table 2
Assessment of sera from horses naturally infected with HeV by ELISA, virus neutralisation, Luminex binding and blocking assays.








HeV  sG Luminex
blocking (% inhibition)
2008/Redlands, QLD/no. 1 1.8 1.83 2048 104 93
2008/Redlands, QLD/no. 2 0.99 1.76 4096 103 91
2008/Redlands, QLD/no. 3 0.57 1.38 128 96 76
2008/Proserpine, QLD/no. 1 1.79 1.63 512 103 77
2008/Redlands, QLD/no. 4 1.7 1.8 2048 105 95
2008/Redlands, QLD/no. 5 1.58 1.87 2048 106 95
2008/Redlands, QLD/no. 6 1.8 1.71 4096 104 85
2008/Hendra, QLD/no. 1 0.44 0.03 16 6 29
2008/Redlands, QLD/no. 7 0.97 1.44 2048 97 81
2006/QLD/no. 1 0.55 0.02 20 4 15
2009/Cawarral/no. 1 0.86 2.18 64 32 61
2009/Cawarral/no. 2 1.32 2.79 1024 78 67
2009/Cawarral/no. 3 1.38 1.81 16 104 90
2009/Cawarral/no. 4 1.52 2.8 16 103 89
1994/Hendra, QLD/no. 1 1.40 1.58 640 104 95
1994/Hendra, QLD/no. 2 1.63 1.66 640 104 95
1994/Hendra, QLD/no. 3 1.66 1.71 1280 104 92
1994/Hendra, QLD/no. 4 0.61 0.15 20 35 18
1994/Hendra, QLD/no. 5 1.15 1.52 640 104 94
1994/Hendra, QLD/no. 6 1.11 1.54 640 100 88
1994/Hendra, QLD/no. 7 1.47 1.64 640 103 93
Assay positive detection thresholds are: HeV iELISA OD > 0.2; HeV sG ELISA S/P > 0.4; HeV virus neutralisation titre ≥2; HeV Luminex binding % P ≥ 5%; He V Luminex blocking
%I  ≥ 15%.
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Table  3
Assessment of assay thresholds using results from ROC analysis.
(a) Luminex blocking assay
Criterion Sensitivity 95% CI Specificity 95% CI
> 12.45 100.00 83.9–100.0 100.00 98.6–100.0
>  15 95.24 76.2–99.9 100.00 98.6–100.0
(b)  Luminex binding assay
Criterion Sensitivity 95% CI Specificity 95% CI
>3.67 100.00 83.9–100.0 99.28 97.4–99.9
>5  95.24 76.2–99.9 99.64 98.0–100.0
allowed for improvements, particularly to reduce the frequency of
non-specific reactions encountered in ELISAs using crude disrupted
virus. As a further refinement to testing procedures, this study has
shown that the henipavirus Luminex binding and blocking assays
are effective for HeV serology in the assessment of equine and
canine sera and are advantageous particularly in the resolution of
indeterminate ELISA results without further recourse to virus neu-
tralisation serology. While progressive validation of this approach
remains dependent on the availability of infrequent positive sam-
ples generated in episodic outbreaks, the Luminex assay have been
shown to perform better than the conventional ELISAs currently in
use at AAHL in terms of both sensitivity and specificity.
The results supplement other serological studies in Australia
and Africa which have utilised Luminex serology assays to demon-
strate evidence for henipavirus infection (Bossart et al., 2005, 2007;
Hayman et al., 2011; Peel et al., 2012, 2013; Dups et al., 2012;
Playford et al., 2010). In particular, this study has explored more
extensively the relative performance characteristics of ELISAs and
Luminex and evaluated more recent developments in assessments
of post-infection canine sera and post vaccination equine sera.
The Luminex binding assay has a more conventional indirect
detection format, allowing recognition of both neutralising and
non-neutralising antibodies targeting the HeV G protein (Bossart
et al., 2007). Analytical sensitivity relative to the HeV virus neu-
tralisation favoured the Luminex by a factor of approximately 2,
though this margin is of no practical value for predicting diag-
nostic performance. The Luminex receptor-blocking assay has a
narrower specificity, being limited to antibodies in the test sample
which may  interfere with binding of the labelled ephrin B receptor.
Hence the assay is described as a neutralisation test surrogate and
has been shown to be uninfluenced by binding of non-neutralising
monoclonal antibodies against G protein (Bossart et al., 2007). The
assay therefore has potential as a confirmatory test for specificity
of results from the binding assay or as a test that would remove the
need for confirmatory virus neutralisation serology. Evidence for
this higher specificity is also suggested from analytical specificity
results presented. However the test has a detection range approxi-
mately half that of the virus neutralisation; relative to the binding
assay analytical sensitivity is reduced by a nine-fold factor. Nev-
ertheless the relevance of this margin to diagnostic performance
is difficult to assess, particularly given the dearth of post infection
antibody-positive sera. Other than for the expected cross-reactions
with NiV, both assays showed a high level of analytical specificity.
Diagnostic specificity was assessed in Luminex binding and recep-
tor blocking assays using a total of 277 (binding) and 267 (blocking)
sera with an assigned negative status as determined by virus neu-
tralisation and/or ELISA. All produced low MFI  results and allowed
provisional thresholds to be set at 5% percent positive control and
15% for the receptor blocking assay.
The commercial release in 2012 of the Equivac HeV vaccine
for use in Australian horse populations (companion, farm and rac-
ing) has resulted necessarily in a modification to the “fitness for
purpose” of serology assays which incorporate the HeV G protein,
including the Luminex and ELISA assays described in this publica-
tion. The vaccine induces detectable antibody against G protein as
is evident in this assessment of 54 vaccinated horses which showed
an average of 93%P control. As a consequence and for external
reporting, in reports of results for antibody against G protein, a
comment is inserted “The currently available serology assays do not
distinguish between antibodies due to natural infection and those due
Table 4
Evaluation of HeV detectable antibody in canine field sera collected from dogs located in proximity to a confirmed equine HeV infection.











2011/Mount Alford,QLD/no. 1 2.82 (0.09) 3.02 Positive with a titre >1:16 22,182 88 Positive
2011/Mount Alford,QLD/no. 2 2.53 (0.22) 3.17 Positive with a titre of 128 12,241 61 Positive
2011/Biddadaba, QLD/no. 1 0.34 (0.11)* 0.05 Negative 105 3 Negative
2011/Biddadaba, QLD/no. 2 0.31 (0.14)* 0.02 Negative 74 0 Negative
2011/Biddadaba, QLD/no. 3 0.22 (0.15)* 0.02 Negative 43 0 Negative
2011/Biddadaba, QLD/no. 4 0.25 (0.11)* 0.03 Negative 89 0 Negative
2011/Biddadaba, QLD/no. 5 0.23 (0.06)* 0.02 Negative 83 1 Negative
2011/Biddadaba, QLD/no. 6 0.33 (0.12)* 0.02 Negative 95 1 Negative
2011/Wardell, NSW/no. 1 0.16 (0.05)* 0.03 Negative 144 1 Negative
2011/Zillmere, QLD/no. 1 3.08 (2.96)* 1.84** Negative 97 1 Negative
2011/Zillmere, QLD/no. 2 3.32 (3.42)* 1.94** Negative 109 1 Negative
2011/Zillmere, QLD/no. 3 2.88 (2.52)* 2.64** Negative 107 1 Negative
2011/Chinchilla, QLD/no. 1 0.1 (0.05) 0.06 Negative 110 2 Negative
2011/Currumbin Valley, QLD/no. 1 0.38 (0.15)* 0.17 Negative 80 1 Negative
2011/Tintenbar, NSW/no. 1 0.59 (0.44)* 0.18 Insufficient sera*** 57 0 Negative
2012/Mackay, QLD/no. 1 0.25 (0.06)* 0.02 Indeterminate: sample toxicity
at dilutions less than 1:16***
33 2 Negative
2012/Mackay, QLD/no. 2 0.2 (0.05)* 0.01 Negative 229 1 Negative
* Inconclusive result due to binding in mock antigen well.
** Non-specific sG ELISA result.
*** These animals were negative for HeV RNA by PCR.
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to vaccination. Any positive result must be interpreted in the context of
the animal’s vaccination history”. This limitation is presently being
addressed at this laboratory through the development of ELISA
and Luminex assays which are specific for alternative target pro-
teins such as M,  F and/or N. The successful development of these
assays will provide the necessary tools for differentiating infected
from vaccination-derived antibody, commonly referred to as the
DIVA (differentiating infected and vaccinated animals) approach.
Instances which may  be affected by the qualification applied to the
results of assays detecting anti-G antibody would include assess-
ment of vaccinated (or possibly vaccinated) animals for the absence
of HeV exposure. This is expected to become necessary most fre-
quently should an outbreak occur in the vicinity of vaccinated
animals. For the international movement of vaccinated horses, the
preferred option is considered to be the recognition of a vaccina-
tion certificate without recourse to laboratory testing; recently this
process has been allowed by Hong Kong.
While the zoonotic potential of HeV has been evident since
the initial outbreak and subsequent laboratory based studies
(Williamson and Torres-Velez, 2010), the detection in 2011 and
2012 of natural HeV infection in dogs has been a significant devel-
opment in the epidemiology of this virus. As there is evidence
that these infections can be asymptomatic, laboratory testings
for agent and antibody will be key investigative approaches. This
study provides some evidence for the potential use of Luminex
in canine HeV antibody assessment; in addition it should be
noted that indirect ELISA-based approaches may  be prone to non-
specific binding effects which lessen confidence in results. However
Luminex binding and blocking assay results correlated well with
results using virus neutralisation. While validation studies are
required to establish fully the relative merits of the assays, these
early determinations are favourable for the use of Luminex.
The results obtained in this study involving horses and dogs sup-
plement the findings by Bossart et al. (2008) to demonstrate the
potential for henipavirus Luminex assays to become used widely
for diagnostic henipavirus serology. Other diagnostic laboratories
in Australia are currently developing microsphere immune-assays
for detection of HeV which could allow the use of this assay across
Australia for diagnostic use in the future. Advantages, evident for
the henipavirus Luminex binding and blocking assays include short
testing time, a high level of sensitivity and specificity, the absence of
a requirement for PC4 bio-containment and multiplexing capabil-
ity allowing simultaneous investigation for several disease agents.
A challenge is presented in the context of applying the novel
assay (Luminex) for detection of an emerging disease for which
very few retrospective positive samples are available to determine
validation and fitness. The frequent requirement to assess acute
disease samples for antibody which may  not have developed serves
to emphasise the need for both agent and antibody detection in
diagnostic evaluations. Significantly, this assessment of Luminex
assays used sera that were determined as positive in virus neu-
tralisation and/or ELISA and it is therefore not possible to infer the
diagnostic characteristic of the assay under these limitations. With
performance characteristics that are equal to or better than ELISA
and virus neutralisation, it is predicted that Luminex assays will
become a versatile tool in disease investigation, epidemiological,
and surveillance studies for the detection of henipavirus specific
antibodies in the future.
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